AIM ImmunoTech (AIM) Issues Letter to Stockholders
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/30/2026
- S&P 500, Nasdaq register best quarter since 2020 despite Iran war
- Dollar pushes higher, yen sinks to 40-year low
- NVIDIA stock gains as SemiAnalysis sees H2 data center revenue 20% above consensus
- Citi says bearish flows are building in Nasdaq and S&P 500
- Patrick and LCI Industries to merge in all-stock deal
- Mizuho says ignore Apple noise, flags key catalyst for Micron and memory in H2
- EchoStar Prepares Dish DBS Bankruptcy Filing as Soon as Tuesday - WSJ
- Strategy stock jumps 7% as firm shifts to active capital management
- New leader board: Citi refreshes AI compute semiconductor picks
- S&P 500, Nasdaq register best quarter since 2020 despite Iran war
AIM ImmunoTech Issues Letter to Stockholders
March 6, 2023 8:45 AM ESTYear marked by noteworthy operational execution and clinical development progress across pipeline
Company reiterates commitment to continued communication and activity with the investment and scientific communities
Poised to achieve multiple clinical and regulatory value-driving milestones in 2023
OCALA, Fla., March 06, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM)Â (AIM or the... More
